Skip Navigation



NDT Advance Access published online on February 13, 2006
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfl013
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/4/846    most recent
gfl013v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Miyata, T.
Right arrow Articles by Strihou, C. v. Y. d.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miyata, T.
Right arrow Articles by Strihou, C. v. Y. d.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2006]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received December 27, 2005
Accepted January 12, 2006

Editorial Comment

Renoprotection of angiotensin receptor blockers: beyond blood pressure lowering

Toshio Miyata 1 * and Charles van Ypersele de Strihou 2

1 Institute of Medical Sciences and Division of Nephrology, Hypertension and Metabolism, Tokai University School of Medicine, Kanagawa, Japan
2 Service de Nephrologie, Universite Catholique de Louvain, Brussels, Belgium

* To whom correspondence should be addressed.
Toshio Miyata, E-mail: t-miyata{at}is.icc.u-tokai.ac.jp



This article has no Abstract. Keywords: advanced glycation end products; blood pressure; chronic hypoxia; diabetic nephropathy; oxidative stress; PAI-1; renin-angiotensin system.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
Y. Izuhara, T. Sada, H. Yanagisawa, H. Koike, S. Ohtomo, T. Dan, S. Ito, M. Nangaku, C. van Ypersele de Strihou, and T. Miyata
A Novel Sartan Derivative With Very Low Angiotensin II Type 1 Receptor Affinity Protects the Kidney in Type 2 Diabetic Rats
Arterioscler Thromb Vasc Biol, October 1, 2008; 28(10): 1767 - 1773.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
F. F. Hou, D. Xie, X. Zhang, P. Y. Chen, W. R. Zhang, M. Liang, Z. J. Guo, and J. P. Jiang
Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: A Randomized Controlled Study of Benazepril and Losartan in Chronic Renal Insufficiency
J. Am. Soc. Nephrol., June 1, 2007; 18(6): 1889 - 1898.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.